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Abstract
Purpose The primary objective of this study was to
access the potential eVects of trabectedin on the QT/QTc
interval in patients with locally advanced or metastatic
solid tumors.
Methods Patients (n = 75) who had received ·3 previous
lines of chemotherapy and had either relapsed or had pro-
gressive disease were enrolled. Patients were administered
3-h intravenous infusions of placebo (saline) on day 1 and
trabectedin (1.3 mg/m2) on day 2. Time-matched serial trip-
licate ECG recordings and pharmacokinetic blood samples
were collected over 24 h on both days. Heart rate corrected
mean QT intervals and changes from predose baseline in
QTc (QTc) were assessed. The diVerence in QTc
between trabectedin and placebo was calculated at each
time point (QTc).
Results The upper limits of the 90% conWdence interval
for QTcF and QTcB at all time points were less than
the prespeciWed noninferiority margin of 10 ms
(·6.65 ms). No patient had a QTc > 500 ms or a time-
matched increase from baseline in QTc > 60 ms at any time
point. Regression analyses indicated QTc was poorly
correlated with trabectedin concentration. No adverse
events suggestive of proarrhythmic potential were reported.
Conclusion Trabectedin did not prolong the QTc interval.
Safety and pharmacokinetic proWles of trabectedin were
similar to that observed in other ovarian and breast cancer
studies.
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Introduction
Trabectedin is a tris, tetrahydroisoquinoline alkaloid origi-
nally isolated from the marine ascidian, Ecteinascidia turbi-
nata, and now produced synthetically. It binds to the minor
groove of DNA and interacts with proteins of the DNA-
repair machinery [1], disrupting the cell cycle and inhibiting
cell proliferation [2]. Trabectedin is approved in several
countries including the European Union (not approved in the
United States) for patients with advanced soft tissue sarcoma
after treatment failure with anthracycline and ifosfamide. It is
also approved in the European Union in combination with
pegylated liposomal doxorubicin for the treatment of patients
with relapsed, platinum-sensitive ovarian cancer [3].
In a population pharmacokinetic (PK) analysis, trabect-
edin as a single intravenous (i.v.) infusion for periods of 1,
3, and 24 h showed time-independent and linear PK [4].
Trabectedin is highly bound (94.2%) to plasma proteins [5]
and undergoes extensive metabolism via the cytochrome
P450 system, mainly by the CYP3A4 isoenzyme [6]. The
extensive tissue distribution of trabectedin (distribution
volume of >5,000 L) accounts for the multi-exponential
decline in concentrations in plasma and relatively long ter-
minal half-life of approximately 180 h [4].
The present study was conducted primarily to assess the
potential eVects of therapeutic doses of trabectedin on the
QT/QTc interval duration in patients with advanced solid
tumor malignancies, as recommended in the International
Conference of Harmonization (ICH) E14 guidelines. The
secondary objectives of this study were to assess the safety
and PK of trabectedin and its eVect on patient survival.
Patients and methods
Patients
Seventy-Wve male and female patients (age, 18–65 years,
inclusive) with locally advanced or metastatic solid tumors
who had received not more than 3 lines of systemic chemo-
therapy or were intolerant to standard chemotherapy were
enrolled in the study. Additional inclusion criteria were left
ventricular ejection fraction within normal limit in patients
previously treated with a cumulative anthracycline dose
over 260 mg/m2; supine blood pressure between 90 and
140 mmHg systolic and not more than 90 mmHg diastolic;
a 12-lead electrocardiogram (ECG) consistent with normal
cardiac conduction and function; Eastern Cooperative
Oncology Group (ECOG) performance status of 0–1; and
clinical laboratory values within acceptable limits as prede-
Wned in the protocol. Patients had to be non-smokers (for at
least 6 months before study drug administration) and be
able to receive dexamethasone.
Patients treated with more than 3 prior chemotherapy
regimens and those with previous exposure to trabectedin,
known hypersensitivity to any of the components of the tra-
bectedin (i.v.) formulation or dexamethasone, heart rhythm
disturbances, unusual T- and U-wave (if present) morphol-
ogy, CNS metastasis, cardiac failure, myocardial infarction
or cardiomyopathy, additional risk factors for torsade de
pointes (e.g., heart failure, electrolyte abnormalities, family
history of long QT syndrome) and with any condition likely
to interfere with placement of the ECG electrode and elec-
trical conduction were excluded from the study. Further-
more, patients at screening receiving medication that
prolonged QT interval or who were on CYP3A4 inhibitors
or inducers and with current clinically signiWcant other
medical illness were excluded. Women who were breast-
feeding and those planning to become pregnant during the
study were also excluded.
Study design
This was a single-blind (patients blinded to treatment),
multicenter, placebo-controlled, sequential design study. It
included a screening period of up to 21 days during which
patient eligibility was assessed, followed by a treatment
phase of 2 single-dose treatments. On day 1 of the treat-
ment phase, the patients were administered placebo (normal
saline, 3-h i.v. infusion), and on day 2, the patients received
trabectedin (1.3 mg/m2, 3-h i.v. infusion). Dexamethasone
(20 mg or equivalent, i.v.) was administered 30 min before
the i.v. infusions on day 1 and day 2. Granisetron or ondan-
setron was also administered 30 min before the i.v. infu-
sions if additional antiemetic therapy was considered
necessary. Twelve-lead ECGs were obtained by a GE
MAC® 1200 resting 12-lead ECG device (General Electric
Healthcare) with the capacity for digital signal processing
and were extracted by a core ECG laboratory (MDS
Pharma Services, Ontario, Canada). Blood samples were
collected at prespeciWed times for the determination of tra-
bectedin concentrations in plasma.
This study was conducted in accordance with the ethi-
cal principles originating in the provisions of the World
Medical Association Declaration of Helsinki and its
amendments concerning medical research in humans and
in conformance with all local laws and regulations. Docu-
mentation procedures complied with ICH guidelines.
Study procedures were designed to ensure adherence to
Good Clinical Practices and the Code of Federal Regula-
tions 21 and in compliance with the respective protocols.
Written consent was obtained from all patients before
performance of any study-related activity. Approval for
the study was obtained from an Independent Ethics Com-
mittee or Institutional Review Board at each participating
investigative site.Cancer Chemother Pharmacol (2012) 69:341–350 343
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Evaluations
ECG acquisition
On days 1 and 2, serial ECGs (10-s digital ECGs) were
recorded in triplicate (maximum of 2 min between each
of the triplicate) at each of the following time points:
predose and at 1, 2, 2.75, 4, 6 and 8 h after the start of
the infusion. Electrocardiograms were also collected
24 h after trabectedin administration on day 2. The pre-
dose (baseline) ECG assessments were recorded within
30 min before the dose of placebo and trabectedin.
Patients remained in the comfortable supine position for
at least 10 min preceding and following the ECG trac-
ings. Physical activity, position, external stimulation,
and meal ingestion were closely regulated to keep physi-
cal activity and emotional excitement to a minimum.
Patients were allowed to be ambulatory between ECG
assessments.
ECG analysis and interpretation
The ECG tracings were evaluated by the third-party central
ECG laboratory, which was blinded to treatment (i.e., study
day) and time. All ECGs were read by a certiWed cardiolo-
gist. The ECGs were measured by digital on-screen cali-
pers, using a semi-automated method (prepositioning of the
cursors by the automatic analysis followed by an over-read
of each ECG by a cardiologist). To correct for possible
eVects of heart rate, Fridericia (QTcF = QT/RR1/3) and
Bazetts (QTcB = QT/RR1/2) corrections were used as the
primary and secondary methods, respectively. The Wnal
value for each QTc was the average of three complexes. All
recordings, including the waveforms with interval measure-
ments, were digitally stored.
Pharmacokinetic evaluations
Peripheral venous blood samples for the determination of
trabectedin plasma concentrations were collected predose
and following placebo (day 1) and trabectedin (day 2)
administration. The blood samples were time-matched to
the ECG measurements and collected within 5 min after
the last ECG tracing of the triplicate ECGs was recorded.
Blood samples were collected at 2 h 45 min after dosing
with placebo on day 1 to verify the absence of trabect-
edin (as time required to reach the maximum concentra-
tion [tmax] of trabectedin was observed to be 2–3 h in
previous studies). The concentrations of trabectedin in
plasma were determined by a validated liquid chromatog-
raphy–mass spectrometry/mass spectrometry (LC–MS/
MS) method at the Slotervaart Hospital in Amsterdam,
The Netherlands.
Safety evaluations
Safety evaluations included assessment of treatment-emer-
gent adverse events (TEAEs), clinical laboratory tests, vital
signs measurements, and physical examination. All TEAEs
were evaluated in terms of intensity, duration, seriousness,
and outcome.
Statistical analysis
Sample size determination
The intrasubject standard deviation for QTcF was
assumed to be 10 ms. For a sample size of 52 patients
(completers) and assuming the true diVerence in means
equals 5 ms, the probability that the upper limit of the two-
sided 90% conWdence interval (CI) for the QTc at each
time point would fall below 10 ms was estimated to be
80%. Approximately 60 patients were to be enrolled to
ensure that at least 52 evaluable patients completed all
required assessments.
Statistical methods
ECG-related variables were calculated for all patients who
received treatment on both days, had predose baseline val-
ues for placebo and trabectedin, and had at least one paired
postdose value (evaluable analysis set). The primary phar-
macodynamic parameter was the diVerence in the change
from predose (QTc) at each scheduled time point between
trabectedin (day 2) and placebo (day 1). The predose time
point on day 2 was also the 24-h time point for day 1. For
each patient, the diVerence in QTc between trabectedin
and placebo was calculated at each time point
(QTc = QTc for trabectedin minus QTc for placebo
for the patient at the same time point). Mean QTc and
the 90% CI for QTc were calculated at each time point.
A mixed eVect analysis of variance (ANOVA) model
was Wtted with the QTc data as the dependent variable and
treatment (trabectedin, placebo), scheduled time point of
measurement, and treatment by scheduled time point of
measurement interaction as Wxed eVects and patients as a
random eVect. Using the estimated least square means and
intrasubject variance obtained from this model, 2-sided
90% CI was calculated for QTc at each scheduled time
point. Non-inferiority, deWned as the absence of QTc pro-
longation when compared with placebo, was concluded if at
each scheduled time point the upper limit of the two-sided
90% CI fell below 10 ms. Mean QTc, QTc, and QTc
were summarized by using descriptive statistics at each
time point and by treatment.
Incidence count and percentage of patients with QTc
values above the following limits were summarized: QTc344 Cancer Chemother Pharmacol (2012) 69:341–350
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interval >450 ms, QTc interval >480 ms, and QTc interval
>500 ms. Incidence count and percentage of patients with
QTc increase from predose (QTc) for each treatment and
time point were summarized for the following categories:
QTc interval increase from baseline >30 ms and QTc inter-
val increase from baseline >60 ms. Additional analyses
were performed after the QTc results became available to
summarize the incidence count and percentage of patients
whose QTc values were reduced from baseline by >30 ms,
>60 ms, and absolute QTc intervals that were <360 and
<320 ms.
The intervals RR, PR, and QRS were listed over time for
each patient and treatment. For each treatment group and
time point of measurement, the data were summarized
using descriptive statistics. The number and percentage of
patients who experienced PR or QRS interval abnormalities
based on the following criteria were summarized by treat-
ment: PR interval >200 ms and QRS interval >120 ms.
Relationship between plasma trabectedin 
and QT/QTc interval changes
Analysis using a linear mixed eVects model was performed
with QTc as dependent variable and trabectedin concen-
tration as a predictor and patients as random eVect. The ran-
dom intercept model was selected as the best Wt model, and
the predicted value of QTc (along with 90% CI) was
estimated at the mean Cmax values of trabectedin based on
this model.
Morphological analyses of heart rate ECG waveforms
Mean heart rate (HR) and corresponding changes from
baseline were summarized using descriptive statistics by
treatment group and time point. T-wave morphology and
abnormal U-waves were summarized by treatment group.
Safety evaluations
Safety analyses were summarized with descriptive statis-
tics, for the treated analysis set that was composed of all
patients who received at least 1 dose of study drug or pla-
cebo and provided at least one postdose measurement.
Results
Patient enrollment, demographics, 
and baseline characteristics
This single-blind study enrolled 75 patients at 20 sites in 7
countries from October 14, 2008 to April 16, 2009. Of the
enrolled patients, 72 completed the study, and 3 patients
died within 30 days after study treatment. All 75 patients
were included in the treated analysis set, and 74 patients
were included in the evaluable analysis set (one patient who
received trabectedin and placebo in the reverse order was
not included).
The demographic and baseline characteristics of the
enrolled population are given in Table 1. The most com-
mon tumor types were sarcoma (33%) and ovarian cancer
(31%). Most patients (99%) had received prior cancer
therapy.
Table 1 Demographic and baseline characteristics
BMI body mass index, BSA body surface area, ECOG Eastern Cooper-
ative Oncology Group
Total (N =7 5 )
Age (years), Mean (SD) 50.1 (11.03)
Sex, n (%)
Female 51 (68)
Male 24 (32)
Race, n (%)
White 51 (68)
Asian 23 (31)
Other 1 (1)
BMI (kg/m2), mean (SD) 25.6 (5.45)
BSA (m2), mean (SD) 1.8 (0.22)
Baseline ECOG performance status, n (%)
0 31 (41)
1 44 (59)
Tumor type, n (%)
Sarcoma 25 (33)
Breast 11 (15)
Ovarian 23 (31)
Other 16 (21)
Stage of disease, n (%)
II 8 (11)
III 15 (20)
IV 51 (68)
NA 1 (1)
Number of site involvement at 
baseline, mean (SD)
1.8 (1.37)
Total no. of patients with previous 
chemotherapy, n (%)
74 (99)
Antineoplastic agents 74 (99)
All other therapeutic products, n (%) 4 (5)
Endocrine therapy 4 (5)
Antipsoriatics 3 (4)
Cough and cold preparations 3 (4)
Antianemic preparation 2 (3)
Sex hormones and modulators 
of the genital system
1 (1)Cancer Chemother Pharmacol (2012) 69:341–350 345
123
ECG analysis
QTcF and QTcB
As mentioned earlier, for QT interval assessment, Frideri-
cia and Bazetts methods were used to correct for heart rate.
The appropriateness of the correction factors was assessed
by simple linear regression of QTc versus the RR interval.
The results indicate that both correction methods were ade-
quate. The analyses resulted in slopes of 0.101 (R2 = 0.12)
and ¡0.065 (R2 = 0.05) for Fridericia and Bazetts methods,
respectively. The regression analysis of uncorrected QT
versus RR resulted in a slope of 0.435 (R2 = 0.72).
The mean baseline (predose) QTcF and QTcB intervals
were similar before placebo and trabectedin administration
(Tables 2 and 3). The mean QTcF intervals increased dur-
ing the Wrst 4 h after the start of either placebo or trabect-
edin (Table 2). Thereafter, the QTcF intervals declined
gradually to approximate predose values at the time of the
8-h ECG assessments. Small changes were also observed in
the mean QTcB intervals during 24 h after the start of the
placebo or infusions (Table 3).
Table 2 Estimated means and conWdence intervals of the eVect of placebo and trabectedin on the QTcF interval (ms) in patients with advanced
solid tumor malignancies treated with a single dose of 1.3 mg/m2 trabectedin (3-h infusion) (evaluable analysis set)
Sample sizes provided in the table refer to the QTcF results. The descriptive statistical analyses of the trabectedin concentrations included
67–73 patients at each time point
CFB change from base line, CI conWdence interval, ms milliseconds
N Scheduled 
time
Arithmetic 
mean trabectedin 
concentration 
(ng/ml)
Arithmetic 
mean (ms) 
(95% CI)
Arithmetic 
mean (ms) 
CFB (95% CI)
Placebo-adjusted 
LS mean 
CFB (ms) (90% CI)
Placebo (Day 1)
n = 74 Predose – 406.2 
(402.0;410.5)
––
n = 74 1 h – 408.0
(403.6;412.3)
1.7
(0.1;3.4)
–
n = 74 2 h – 411.4
(406.9;415.9)
5.2
(3.2;7.1)
–
n = 74 2 h 45 min – 413.4
(409.0;417.9)
7.2
(5.3;9.1)
–
n = 74 4 h – 415.9
(411.5;420.3)
9.7
(7.3,12.0)
–
n = 74 6 h – 411.5
(407.1;416.0)
5.3
(3.1;7.4)
–
n = 73 8 h – 408.9
(404.8;413.1)
2.5
(0.3;4.8)
–
n = 74 24 h – 409.8
(405.8;413.8)
3.6
(1.2;5.9)
–
Trabectedin 1.3 mg/m2 (Day 2)
n = 74 Predose – 409.8
(405.8;413.8)
––
n = 74 1 h 7.15 410.1
(405.8;414.5)
0.3
(¡1.7;2.4)
¡1.4
(¡3.35;0.51)
n = 74 2 h 8.07 411.3
(406.9;415.8)
1.5
(¡0.8;3.8)
¡3.7
(¡5.68;¡1.63)
n = 72 2 h 45 min 6.98 413.1
(408.5;417.7)
2.7
(0.6;4.8)
¡4.5
(¡6.55;¡2.40)
n = 72 4 h 1.70 413.8
(409.7;417.9)
3.8
(1.5;6.1)
¡5.8
(¡8.19;¡3.45)
n = 73 6 h 0.909 411.0
(407.1;414.9)
1.0
(¡1.3;3.4)
¡4.2
(¡6.26;¡2.22)
n = 73 8 h 0.690 410.2
(406.1;414.4)
0.3
(¡2.3;2.8)
¡2.3
(¡4.82;0.26)
n = 73 24 h 0.443 403.7
(399.4;408.0)
¡6.2
(¡8.7;¡3.8)
¡9.8
(¡12.65;¡6.99)346 Cancer Chemother Pharmacol (2012) 69:341–350
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Smaller  QTcF and comparable QTcB values were
observed following trabectedin administration, relative to pla-
cebo, at the majority of the corresponding time points after
dosing (Tables 2, 3). The mean QTcF ranged from 1.7 ms to
9.7 ms after placebo administration on day 1 and from
¡6.2 ms to 3.8 ms after trabectedin administration on day 2
(Table 2). The mean QTcB ranged from ¡1.2 ms to 9.2 ms
after placebo administration on day 1 and from ¡2.6 ms to
12.5 ms after trabectedin administration on day 2 (Table 3).
The QTcF and QTcB interval placebo-adjusted changes
from baseline in least square means and the corresponding
90% CIs are summarized in Tables 2, 3, and Fig. 1. The upper
limits of the 90% CI for all mean QTcF and QTcB val-
ues were ·6.65 ms at all time points, indicating non-inferior-
ity of trabectedin to placebo with respect to QTc prolongation.
Categorical analyses revealed no patient with an abso-
lute postdose QTcF or QTcB value >500 ms after treatment
with trabectedin or placebo. No patient and 2 patients (3%)
exhibited a QTcF and QTcB > 480 ms, respectively, fol-
lowing treatment with trabectedin. No patient and 1 patient
(1%) had a QTcF and QTcB > 480 ms, respectively, after
placebo. Four patients (5%) and 23 patients (31%) exhibited
Table 3 Estimated means and conWdence intervals of the eVect of placebo and trabectedin on the QTcB interval (ms) in patients with advanced
solid tumor malignancies treated with a single dose of 1.3 mg/m2 trabectedin (3-h infusion) (evaluable analysis set)
Sample sizes provided in the table refer to the QTcB results. The descriptive statistical analyses of the trabectedin concentrations included
67–73 patients at each time point
CFB change from base line, CI conWdence interval, ms milliseconds
N Scheduled 
time
Arithmetic 
mean trabectedin 
concentration 
(ng/ml)
Arithmetic 
mean (ms) 
(95% CI)
Arithmetic 
Mean CFB (ms) 
(95% CI)
Placebo-adjusted 
LS mean CFB (ms) 
(90% CI)
Placebo (Day 1)
n = 74 Predose – 426.3
(422.3;430.3)
––
n = 74 1 h – 425.1
(420.9;429.3)
¡1.2
(¡3.4;1.0)
–
n = 74 2 h – 428.0
(423.4;432.5)
1.7
(¡0.7;4.0)
–
n = 74 2 h 45 min – 430.4
(426.1;434.7)
4.1
(1.7;6.4)
–
n = 74 4 h – 435.4
(431.3;439.5)
9.1
(6.4;11.8)
–
n = 74 6 h – 435.5
(431.0;440.0)
9.2
(6.6;11.7)
–
n = 73 8 h – 433.3
(429.0;437.6)
6.7
(4.1;9.4)
–
n = 74 24 h – 426.4
(422.3;430.4)
0.1
(¡2.3;2.4)
–
Trabectedin 1.3 mg/m2 (Day 2)
n = 74 Predose – 426.4
(422.3;430.4)
––
n = 74 1 h 7.15 423.7
(419.6;427.9)
¡2.6
(¡5.4;0.1)
¡1.4
(¡4.04;1.23)
n = 74 2 h 8.07 426.0
(421.7;430.3)
¡0.3
(¡3.1;2.4)
¡2.0
(¡4.65;0.65)
n = 72 2 h 45 min 6.98 430.8
(426.4;435.1)
4.0
(1.3;6.6)
¡0.1
(¡2.66;2.50)
n = 72 4 h 1.70 439.1
(435.4;442.7)
12.5
(9.6;15.4)
3.4
(0.07;6.65)
n = 73 6 h 0.909 439.0
(435.3;442.7)
12.4
(9.8;15.0)
3.2
(0.56;5.92)
n = 73 8 h 0.690 435.9
(432.0;439.8)
9.3
(6.7;11.9)
2.6
(¡0.38;5.63)
n = 73 24 h 0.443 425.1
(420.8;429.4)
¡1.5
(¡4.7;1.7)
¡1.6
(¡4.83;1.72)Cancer Chemother Pharmacol (2012) 69:341–350 347
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a QTcF and QTcB > 450 ms, respectively, following treat-
ment with trabectedin. Six patients (8%) and 21 patients
(28%) had a QTcF and QTcB > 450 ms, respectively, after
placebo. No patient exhibited an increase in the QTcF or
QTcB from baseline >60 ms. Two patients (3%) and 6
patients (8%) had increase in QTcF and QTcB > 30 ms,
respectively, following treatment with trabectedin. Two
patients (3%) and 4 patients (5%) exhibited an increase in
QTcF and QTcB > 30 ms, respectively, after placebo.
Additional categorical analyses indicated that no patient
had a QTcF and QTcB value of <320 ms. QTcF was <360
ms in 1 patient in association with trabectedin and 1 patient
with placebo. In addition, no patient had a decrease from
baseline in QTcF or QTcB > 60 ms. Three patients (4%)
and 4 patients (5%) had a decrease in QTcF and
QTcB > 30 ms, respectively, following treatment with tra-
bectedin. No patient and 1 patient (1%) exhibited a
decrease in QTcF and QTcB > 30 ms, respectively, after
placebo.
Heart rate, T- and U-wave morphology, and PR and QRS 
intervals
The mean (SD) baseline (predose) HR prior to placebo (day
1) and trabectedin (day 2) administration was 81.2 (12.9)
bpm and 76.9 (10.5) bpm, respectively. Mean HR values
after both i.v. infusions ranged from 76.9–86.0 bpm for pla-
cebo and 73.8–90.0 bpm for trabectedin. At 24 h after tra-
bectedin infusion, the mean HR declined to a value similar
to baseline value prior to placebo infusion (82.6 [11.1]
bpm).
The T-wave morphology was unaltered with trabectedin
treatment, and no pathological U-wave morphology was
observed in this study. The PR and QRS intervals were also
not aVected by trabectedin.
Plasma pharmacokinetics of trabectedin
Plasma samples were available for bioanalysis from a
majority of the enrolled patients (Tables 2 and 3). The
concentration of trabectedin was below the limit of quan-
tiWcation for all plasma samples collected at 2 h 45 min
after start of placebo infusion (day 1). The mean concen-
trations increased over the course of the i.v. infusion
administered on day 2. Maximum concentrations were
observed at an average (SD) of 2.22 (0.65) h after the start
of the trabectedin infusion. The mean (SD) C max value
was 9.24 (3.75) ng/ml. The trabectedin concentrations ini-
tially declined rapidly upon completion of the infusion,
followed by a protracted decrease in the concentrations,
with much lower concentrations observed at the 24-h time
point.
Relationship between plasma trabectedin 
and QT/QTc interval changes
The individual QTc intervals and corresponding trabect-
edin plasma concentrations exhibited a very weak linear
relationship (Fig. 2). For both analyses, the range of
QTc was quite wide as evidenced by the spread of the
data around the regression line. At the mean Cmax of 9.2 ng/
ml in plasma, the mean (90% CI) QTcF was ¡2.53 ms
(¡4.59, ¡0.46 ms) and QTcB was ¡0.68 ms (¡3.26,
1.90 ms).
Safety
Seventy-one (95%) of the 75 patients in the study experi-
enced TEAEs (Table 4). The most frequent adverse events
were nausea (n = 41[55%]), vomiting (n = 39 [52%]),
abnormal hepatic function (n = 24 [32%]), asthenia (n =2 0
[27%]), anorexia (n = 15 [20%]), fatigue (n = 12 [16%]),
and neutropenia (n = 12 [16%]) (Table 4). Three patients
died within 30 days after study treatment. One patient with
oropharyngeal cancer died 12 days after receiving study
drug, due to progressive disease. The second patient expe-
rienced serious grade 3 asthenia and grade 3 vomiting,
5 days after receiving study drug, and died the next day. It
was unknown whether these events caused the sudden
death. The third patient with linitis plastica died due to
euthanasia administered 30 days after study drug at the
request of the patient, due to progressive disease. There
were no clinically noteworthy changes observed in labora-
tory assessments, vital signs, ECGs, and physical examina-
tion in the study. No patient experienced cardiac toxicity in
this study.
Fig. 1 Placebo-adjusted least square mean (§90% conWdence
interval) change from baseline in QTc (QTc) intervals following
treatment with a single dose of trabectedin 1.3 mg/m2 (3-h infusion) in
patients with advanced solid tumor malignancies348 Cancer Chemother Pharmacol (2012) 69:341–350
123
Discussion
Considerable evidence is available demonstrating that some
non-cardiac (i.e., non-antiarrythmic) drugs delay cardiac
repolarization. This eVect can be measured by ECG and
identiWed by prolongation of the QT/QTc interval [7, 8].
Prolongation of the QT/QTc interval has been associated
with the increased susceptibility to arrhythmias, such as the
relatively rare event known as torsades de pointes [8].
Thus, premarketing investigation of the safety of a new
pharmaceutical agent typically includes rigorous character-
ization of its eVects on the QT/QTc interval [9, 10].
In unpublished nonclinical experiments, trabectedin
showed low potential to delay ventricular repolarization. In
hERG-transfected HEK293 cells, trabectedin at a con-
centration of 10¡8 M to 3 £ 10¡6 M (approximately
7.6–2,286 ng/ml) had no signiWcant eVect on the membrane
K + current (IKr). However, at a high concentration
(10¡5 M or 7,620 ng/ml), only a marginal eVect (approxi-
mately 10% reduction relative to solvent control) was
observed. The eVect of a single 1-h i.v. infusion of trabect-
edin 90 g/kg (1,080 g/m2) was also investigated in anes-
thetized cynomolgus monkeys. Relevant eVects on heart
rate, ECG variables (PR, QT, QTcF and QTcV intervals,
and QRS duration), ECG gross morphology and rhythm,
left ventricular variables, cardiac output, stroke volume, or
respiratory variables were not observed.
In clinical trials, trabectedin was found to be eYcacious
and well tolerated in the treatment of several tumor types
including ovarian cancer (1.3 mg/m2, 3-h i.v. infusion
every 3 weeks), breast cancer (0.58 mg/m2, weekly and
1.3 mg/m2 every 3 weeks), and soft tissue sarcoma (1.5 mg/
m2, 24-h i.v. infusion once every 3 week) [11–15].
Although higher doses have been administered to sarcoma
cancer patients, the 3-h infusion of 1.3 mg/m2 used in this
study produced concentrations in plasma that are higher
than those following infusions of longer duration (e.g.,
1.14 ng/ml following 1.5 mg/m2 given as a 24-h i.v. infu-
sion) [16].
The present study was designed to determine as pre-
cisely as possible the eVects of trabectedin on QTc. The
design included a number of characteristics considered to
be important for the systematic evaluation of a drug’s eVect
Fig. 2 Correlation between placebo-adjusted change from baseline in
QTc (QTc) versus concentrations of trabectedin in plasma at corre-
sponding time points following treatment with a single dose of trabect-
edin 1.3 mg/m2 (3-h infusion) in patients with advanced solid tumor
malignancies
Table 4 Summary of treatment-emergent adverse events by body sys-
tem or organ class and dictionary derived term (treated analysis set)
The most common (i.e., ¸5%) treatment-emergent adverse events pro-
vided
MedDRA Medical dictionary for regulatory activities
MedDRA preferred term Total (N = 75)
n (%)
Total number of patients with 
treatment-emergent adverse events
71 (95)
Nausea 41 (55)
Vomiting 39 (52)
Hepatic function abnormal 24 (32)
Asthenia 20 (27)
Anorexia 15 (20)
Neutropenia 12 (16)
Fatigue 12 (16)
Constipation 7 (9)
Anemia 7 (9)
Cough 6 (8)
Enzyme abnormality 5 (7)
Leucopenia 5 (7)
Dizziness 5 (7)
Myalgia 4 (5)
Pyrexia 4 (5)
Pain 4 (5)Cancer Chemother Pharmacol (2012) 69:341–350 349
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on QTc interval prolongation and proarrhythmic potential
in humans (i.e., “thorough QT/QTc study”) [17]. It
included digital ECG data collection in triplicate with rigor-
ous methodology, ECG review by experts, application of
appropriate heart rate corrections of measured QT interval,
analysis of central tendency and categorical analysis, and
characterization of the concentration–eVect relationship by
simultaneous measurement of trabectedin concentrations in
plasma and QTc intervals. Consistent with guidelines, the
criterion for a negative study was determined a priori if the
upper bound of the 90% two-sided CI for the largest time-
matched mean eVect on the QTc excluded 10 ms.
The conventional design of the “thorough QT/QTc”
includes administration of substantial multiples of the
dose of a test drug to normal healthy volunteers who are
not concomitantly taking other medications. These fea-
tures increase the likelihood of observing QTc prolonga-
tion if the test drug exhibits this property. Due to safety
and tolerability concerns, patients with advanced malig-
nancies were enrolled in the present study and were
administered a therapeutic dose (1.3 mg/m2) of trabect-
edin. All patients received an i.v. infusion of placebo (i.e.,
saline) followed by trabectedin in a Wxed sequence. The
crossover design element allowed patients to be their own
control. Random assignment to this sequence versus the
reverse order (i.e., trabectedin followed by placebo), as
recommended in ICH E14, was neither practical nor ethi-
cal since the terminal t1/2 of trabectedin is approximately
180 h [4] and would have required a protracted washout
between the treatment days. As a consequence, only the
patients were blinded to the order of treatments, whereas
the investigator and clinical site personnel were unblinded.
The consequences of the single-blind nature of the study
are likely to be small, since the ECGs were analyzed by
independent reviewers who were blinded to treatment
(i.e., study day) and time.
The standard “thorough QT/QTc” study includes a posi-
tive control, which demonstrates an ability to detect clini-
cally signiWcant prolongation in the QTc interval. It has
been customary to administer patients a single 400 mg oral
dose of moxiXoxacin [18–22]. Due to ethical constraints
and practical considerations, the administration of moxi-
Xoxacin to the patients enrolled in the present study was not
possible. “Thorough QT/QTc” studies also often include a
full-day baseline correction method (to account for certain
uncontrollable factors such as circadian variation, food
eVects, etc) where triplicate ECGs at time-matched points
are collected on the day before the test drug and placebo are
given. However, recent work has provided evidence that
this may not be necessary [23]. With the study design uti-
lized in this present study, where each patient was his or her
own control, predose baseline is considered to be suYcient,
as the diVerence in QTc between drug and placebo for
each patient eVectively accounts for diurnal variation and
other factors that are diYcult or not possible to control.
Trabectedin did not prolong QT/QTc intervals relative to
placebo, in this study. The upper limits of the 90% CI for
all mean QTcF and QTcB values were ·6.65 ms at
all time points indicating non-inferiority of trabectedin to
placebo. Further, no patient had a QTcF or QTcB value that
was >500 ms, a time-matched increase in QTc from
baseline >60 ms in either treatment at any time point, nor a
QTc that was less than 350 ms. Moreover, there were no
reports of sudden death or ventricular arrhythmias, includ-
ing ventricular Wbrillation.
There was a modest increase in mean heart rate
observed with trabectedin relative to placebo at 4 h after
the start of infusion and throughout most of the 24-h obser-
vation period. At 24 h after trabectedin infusion, the mean
heart rate values were similar to baseline values before
placebo infusion. The increase in heart rate with trabect-
edin was of no clinical signiWcance. Rare and sporadic out
of range values were noted for other 12-lead ECG parame-
ters (heart rate, PR interval, QRS interval, T-wave and
U-wave morphology). However, no consistent or particular
association to any treatment (trabectedin or placebo) was
observed.
The safety proWle following administration of a single
therapeutic dose of trabectedin (1.3 mg/m2) was similar to
that reported in previous clinical studies. The most com-
monly reported adverse events were asthenia, abnormal
hepatic function, and vomiting that are consistent with the
known safety proWle of trabectedin. No adverse events sug-
gestive of proarrhythmic potential were observed.
In conclusion, trabectedin at a therapeutic dose of
1.3 mg/m2 administered as a 3-h i.v. infusion did not pro-
long the QTc interval in patients with advanced solid tumor
malignancies in comparison with placebo. Further, the
safety proWle was consistent with previous studies, indicat-
ing trabectedin was well tolerated.
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